Characteristic | Statin therapy | Before matching, N (%) | After matching, N (%) | ||||||
---|---|---|---|---|---|---|---|---|---|
No (N = 337) | Yes (N = 53) | P-value | SMD | No (N = 45) | Yes (N = 45) | P-value | SMD | ||
Age (years) | Mean (SD) | 65.1 (10.0) | 71.6 (7.8) | < 0.0001 | 0.7272 | 70.8 (8.3) | 70.9 (8.0) | 0.9589 | 0.0109 |
Sex | Female | 62 (18.4%) | 19 (35.9%) | 0.0036 | −0.4003 | 16 (35.6%) | 13 (28.9%) | 0.4986 | 0.1430 |
Male | 275 (81.6%) | 34 (64.1%) | 29 (64.4%) | 32 (71.1%) | |||||
ECOG PS | 0 | 125 (37.1%) | 19 (35.9%) | 0.8616 | −0.0258 | 13 (28.9%) | 17 (37.8%) | 0.3711 | 0.1894 |
1–3 | 212 (62.9%) | 34 (64.1%) | 32 (71.1%) | 28 (62.2%) | |||||
Smoking history | Never-smoker | 52 (15.4%) | 16 (30.2%) | 0.0085 | 0.3573 | 14 (31.1%) | 12 (26.7%) | 0.6418 | −0.0982 |
Smoker | 285 (84.6%) | 37 (69.8%) | 31 (68.9%) | 33 (73.3%) | |||||
Immune checkpoint inhibitor | Nivolumab | 196 (58.2%) | 27 (50.9%) | 0.3236 | −0.1453 | 25 (55.6%) | 21 (46.7%) | 0.3990 | −0.1785 |
Pembrolizumab | 141 (41.8%) | 26 (49.1%) | 20 (44.4%) | 24 (53.3%) | |||||
Line of treatment | First | 78 (23.2%) | 17 (32.1%) | 0.1592 | 0.2008 | 14 (31.1%) | 15 (33.3%) | 0.8215 | 0.0476 |
Second or higher | 259 (76.8%) | 36 (67.9%) | 31 (68.9%) | 30 (66.7%) | |||||
Histology | Non-Sq | 243 (72.1%) | 41 (77.4%) | 0.4244 | 0.1211 | 34 (75.6%) | 34 (75.6%) | 1.0000 | 0.0000 |
Sq | 94 (27.9%) | 12 (22.6%) | 11 (24.4%) | 11 (24.4%) | |||||
Clinical stage | Advanced | 262 (77.7%) | 43 (81.1%) | 0.5787 | 0.0839 | 34 (75.6%) | 36 (80.0%) | 0.6121 | 0.1071 |
Recurrent | 75 (22.3%) | 10 (18.9%) | 11 (24.4%) | 9 (20.0%) | |||||
Body mass index (kg/m2) | <  22 | 194 (57.6%) | 19 (35.9%) | 0.0032 | −0.4460 | 23 (51.1%) | 17 (37.8%) | 0.2031 | −0.2708 |
≥ 22 | 143 (42.4%) | 34 (64.1%) | 22 (48.9%) | 28 (62.2%) | |||||
Mutation status (EGFR or ALK) | Othersa | 101 (30.0%) | 9 (17.0%) | 0.0508 | 0.3101 | 4 (8.9%) | 8 (17.8%) | 0.2148 | −0.2638 |
Wild-type | 236 (70.0%) | 44 (83.0%) | 41 (91.1%) | 37 (82.2%) | |||||
PD-L1 tumor proportion score | Othersb | 228 (67.7%) | 34 (64.1%) | 0.6135 | 0.0740 | 30 (66.7%) | 28 (62.2%) | 0.6596 | 0.0930 |
≥ 50% | 109 (32.3%) | 19 (35.9%) | 15 (33.3%) | 17 (37.8%) |